Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cetirizine Dry Syrup · 4 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Cetirizine Dry Syrup | DRUG | - |
Inclusion Criteria: * Children diagnosed as atopic dermatitis * Giving informed consent * Children who have 2 grades or more pruritus score. * Children who require the treatment with external steroid preparation other than face and head. * Children with a pruritus severity of 2. * Mild or severe on...
Cetirizine Dry Syrup is used for perennial allergic rhinitis, atopic dermatitis, and pruritus (itching) associated with cutaneous disease. It is studied in pediatric subjects, with trial populations including children from 2 or 3 years of age. The conditions studied are allergic and dermatologic in nature.
Cetirizine Dry Syrup targets HRH1, the histamine H1 receptor, acting as an antagonist. By blocking HRH1, it interferes with histamine-mediated allergic and pruritic responses. This mechanism underlies its development for allergic rhinitis, atopic dermatitis, and pruritus.
GSK plc, which trades under the ticker GSK, is the developer of Cetirizine Dry Syrup. The company is listed as the sponsor of the clinical trials evaluating this formulation in pediatric allergic and dermatologic conditions.
Cetirizine Dry Syrup is in Phase 3 development. Both of its recorded trials are Phase 3 studies, and both are completed, with no active trials currently listed. It is an investigational formulation studied in pediatric populations.
Cetirizine Dry Syrup has been evaluated in Phase 3 trials including NCT00257595 and NCT00253058 in perennial allergic rhinitis, NCT00257582 in pruritus, and NCT00257569 in atopic dermatitis. All are completed, randomized, double-blind studies in pediatric subjects.
The Cetirizine Dry Syrup clinical program enrolled 316 patients in total across its completed Phase 3 trials. Enrollment included 30 subjects in NCT00257595, 60 in NCT00257582, 278 in NCT00257569, and 286 in NCT00253058.